ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

ClinicalTrials.gov ID: NCT03881696

Public ClinicalTrials.gov record NCT03881696. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 7:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy (OIT) in Food Allergic Children and Adults (CoFAR-11)

Study identification

NCT ID
NCT03881696
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
471 participants

Conditions and interventions

Interventions

  • Double-Blind Placebo-Controlled Food Challenge Based Treatment Other
  • Multi-Allergen Oral Immunotherapy Drug
  • Omalizumab Drug
  • Placebo for Multi-Allergen Oral Immunotherapy Drug
  • Placebo for Omalizumab Drug

Other · Drug

Eligibility (public fields only)

Age range
1 Year to 55 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 21, 2019
Primary completion
Mar 12, 2023
Completion
Jun 30, 2025
Last update posted
Sep 9, 2025

2019 – 2025

United States locations

U.S. sites
10
U.S. states
10
U.S. cities
10
Facility City State ZIP Site status
Arkansas Children's Hospital Research Institute: Department of Pediatrics, Allergy & Immunology Little Rock Arkansas 72202
Stanford School of Medicine: Sean N. Parker Center for Allergy & Asthma Research Stanford California 94305
National Jewish Health: Division of Pediatric Allergy and Clinical Immunology Denver Colorado 80206
Emory University School of Medicine: Children's Healthcare of Atlanta Pediatrics Atlanta Georgia 30307
Johns Hopkins Children's Center: Department of Allergy & Immunology Baltimore Maryland 21287
Massachusetts General Hospital, Department of Medicine: Allergy & Clinical Immunology Unit Boston Massachusetts 02114
Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology New York New York 10029
North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology Chapel Hill North Carolina 27599-7000
Children's Hospital of Philadelphia: Division of Allergy and Immunology Philadelphia Pennsylvania 19104
University of Texas Southwestern Medical Center: Division of Allergy and Immunology Dallas Texas 75390

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03881696, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 9, 2025 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03881696 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →